分化型甲状腺癌中PSMA表达与摄碘、18FDG摄取及患者结局的关联
该研究对44例颈部持续/复发分化型甲状腺癌再手术患者进行PSMA免疫组化分析,发现68%患者至少有一个PSMA阳性病灶,在碘难治患者中18FDG阳性者PSMA阳性比例和表达强度更高,强表达与更短无进展生存相关。
要点
- 68%颈部持续/复发DTC患者存在PSMA阳性病灶。
- 碘难治患者中18FDG阳性者PSMA阳性比例和表达强度更高。
- PSMA强表达(IRS≥9)与更短无进展生存相关。
核心结论
- 颈部持续/复发DTC中约三分之二存在PSMA表达,与不良预后因素相关。
- PSMA强表达与更短无进展生存相关。
研究设计与样本
- 回顾性分析44例2006至2018年接受颈部再手术的连续DTC患者。
- 采用CD31和PSMA免疫组化,以免疫反应评分(IRS)量化PSMA表达。
- 术前评估RAI和18FDG摄取,中位随访6.5±3.7年。
主要发现
- RAI阴性患者中,18FDG阳性者PSMA阳性比例更高(79% vs 25%,P<0.01),平均IRS更高(4.0 vs 1.0,P=0.01)。
- 平均IRS在年龄≥55岁、原发肿瘤>40 mm或侵袭性亚型患者中更高,且与末次随访时结构性病变相关。
- PSMA强表达(IRS≥9)与更短无进展生存相关。
关键数值与推荐
- PSMA阳性定义为IRS≥2,强表达定义为IRS≥9。
- RAI阴性患者中18FDG阳性者PSMA阳性比例79% vs 25%(P<0.01)。
- 18FDG阳性者平均IRS 4.0 vs 1.0(P=0.01)。
临床怎么用
- PSMA表达与不良预后因素相关,或可为碘难治性DTC管理提供新视角。
- 该研究为初步探索,尚不能据此改变临床决策。
局限性
- 样本量小(44例),为单中心回顾性研究。
- 作者称其为初步研究,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Little is known about prostate-specific membrane antigen (PSMA) expression in patients with cervical involvement of differentiated thyroid cancer (DTC). OBJECTIVE: We investigated PSMA expression in neck persistent/recurrent disease (PRD) using immunohistochemistry and the association with radioiodine (RAI) or 18-fluorodeoxyglucose (18FDG) uptake, and patient outcome. DESIGN, SETTING, AND PATIENTS: Data from 44 consecutive DTC patients who underwent neck reoperation from 2006 to 2018 in a comprehensive cancer center. MAIN OUTCOME MEASURE(S): Immunostaining was performed with vascular endothelial marker CD31 and PSMA. PSMA expression was quantified using the immunoreactive score (IRS). RAI and 18FDG uptake were assessed before surgery using posttherapeutic RAI scintigraphy and 18FDG positron emission tomography with computed tomography. Mean follow-up after reintervention was 6.5 ± 3.7 years. RESULTS: Thirty patients (68%) showed at least 1 PSMA-positive lesion (IRS ≥ 2) with similar proportions in RAI-positive and RAI-negative patients (75% vs 66%). In RAI-negative patients, however, the proportion of PSMA-positive disease (79% vs 25%, P < 0.01) and the mean IRS (4.0 vs 1.0, P = 0.01) were higher in 18FDG-positive than in 18FDG-negative patients. Furthermore, mean IRS was higher in patients ≥ 55 years, large primary tumors (>40 mm) or aggressive subtypes, and was correlated with structural disease at last follow-up. Strong PSMA expression (IRS ≥ 9) was associated with shorter progression-free survival (PFS). CONCLUSIONS: Our findings show that PSMA expression was present in two-thirds of patients with neck PRD, that it was related to poor prognostic factors and that very high expression was associated with poorer PFS. This preliminary study may offer new perspectives for the management of RAI-refractory DTC.
引用
- Ciappuccini R, Saguet-Rysanek V, Giffard F, et al. PSMA Expression in Differentiated Thyroid Cancer: Association With Radioiodine, 18FDG Uptake, and Patient Outcome. J Clin Endocrinol Metab. 2021. PMID: 34331544. doi:10.1210/clinem/dgab563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。